Zydus Cadila gets USFDA nod for Tizanidine tablets
Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for treatment of muscle spasms Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Tizanidine Tablets USP Zydus Cadila partners Medicure to launch cholesterol drug in US
Drug firm Zydus Cadila has entered into a definitive agreement with US-based Medicure International Inc to commercialise its new drug application product pitavastatin magnesium in the US. The la Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S. Zydus Cadila receives USFDA's final approval to market sedative injection
The injection will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Dexmedetomidine Hydrochloride Injection Announcement under Regulation 30 (LODR)-Press Release / Media Release
'Cadila Healthcare's Moraiya facility successfully completes USFDA inspection.' Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share
Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these Press Release On The Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2017.
Press Release on the unaudited financial results for the quarter / nine months ended on December 31, 2017. Financial Results For The Quarter / Nine Months Ended 31/12/2017.
Financial Results for the quarter / nine months ended 31/12/2017.